

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	Fibroblast growth factor receptor 1 (FGFR1; CD331)	<p><i>In vitro</i> studies identified a series of acenaphtho[1,2-<i>b</i>]pyrrole derivatives that inhibit FGFR1 and help treat cancers. An ELISA-based drug screening platform showed that the derivative selectively inhibited FGFR1 compared with other FGFRs and tyrosine kinases. In FGFR1-expressing human pancreatic and bladder cancer cell lines, compared with control cells, the derivatives had submicromolar antiproliferative activity. Next steps could include testing the compounds in animal models.</p> <p><b>SciBX 4(23); doi:10.1038/scibx.2011.652</b> <b>Published online June 9, 2011</b></p>	Patent and licensing status unavailable	<p>Chen, Z. <i>et al.</i> <i>J. Med. Chem.</i>; published online April 25, 2011; doi:10.1021/jm200258t <b>Contact:</b> Xuhong Qian, East China University of Science and Technology, Shanghai, China e-mail: <a href="mailto:xhqian@ecust.edu.cn">xhqian@ecust.edu.cn</a> <b>Contact:</b> Yufang Xu, same affiliation as above e-mail: <a href="mailto:yfxu@ecust.edu.cn">yfxu@ecust.edu.cn</a> <b>Contact:</b> Hua Xie, Chinese Academy of Sciences, Shanghai, China e-mail: <a href="mailto:hxie@jding.dhs.org">hxie@jding.dhs.org</a></p>